case_images: PMC10117981_01
case_images: CT imaging changes in the course of furomertinib treatment.
  (A, B) CT imaging changes of liver. (C) CT imaging changes of pancreas. Arrow: Hepatic metastasis; Dotted line: Hepatic abscess.
case_images: fonc-13-1151178-g001.jpg
case_images: PMC10117981_01_fonc-13-1151178-g001.jpg
case_images: f1
case_images: The progression-free survival (PFS) of furmonertinib was 4.7 months ( Figures 1 ,  2 ).
case_images: CA19-9 changes throughout the process.
case_images: fonc-13-1151178-g002.jpg
case_images: PMC10117981_01_fonc-13-1151178-g002.jpg
case_images: f2
case_images: The progression-free survival (PFS) of furmonertinib was 4.7 months ( Figures 1 ,  2 ).
case_images: Flow chart of treatment.
case_images: fonc-13-1151178-g003.jpg
case_images: PMC10117981_01_fonc-13-1151178-g003.jpg
case_images: f3
case_images: CT showed that liver metastases increased and enlarged compared with the previous period, with the largest being about 5.7cm x 3.6cm, suggesting that the effect of nimotuzumab combined with chemotherapy was not good ( Figure 3 ).